Transcatheter valve replacement, especially transcatheter aortic valve implantation (TAVI), took center stage at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium this fall in...
St. Jude Medical Inc. said it plans to acquire AGA Medical Holdings Inc. for about $1.3 billion. The purchase will expand St. Jude’s cardiac device offerings with a portfolio of transcatheter...
October 15, 2010 – An investigational trial of Medtronic’s CoreValve transcatheter aortic valve has been approved by the U.S. Food and Drug Administration (FDA) today. The investigational device...
Transcatheter valve therapies were among the hottest topics at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) symposium and the key presentation was the very positive first release of...
September 14, 2010 – Transcatheter valves, drug-eluting balloons and the latest stent comparison trial data are among the top three trends at Transcatheter Cardiovascular Therapeutics (TCT) 2010...
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is a major risk factor for developing emboli leading to stroke. A new approach to preventing embolisms and stroke is...
Heart failure is a progressively debilitating disease that dramatically decreases the life expectancy and quality of life of affected patients. Nearly 5.8 million Americans are diagnosed with...
In addition to the FDA-cleared Gore Helex and the AGA Amplatzer transcatheter devices for atrial septal defects (ASDs), there are several others in development or already cleared for use outside...
Transcatheter structural heart repair devices deployed in the cath lab have largely replaced open-heart surgery as the therapy of choice. Percutaneously deployed septal occluders make it possible...
